What Revolution Medicines Investors Need to Know

By Tamara Parker • Wednesday, August 06 09:55 • Permanent Link

Shares of Health Care sector company Revolution Medicines moved -0.7% today, and are now trading at a price of $38.13. The Mid-Cap stock's daily volume was 157,674 compared to its average volume of 2,209,766. The S&P 500 index returned a 0.0% performance.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company is based in Redwood City and has 616 full time employees. Its market capitalization is $7,102,398,976.

12 analysts are following Revolution Medicines and have set target prices ranging from $57.0 to $88.0 per share. On average, they have given the company a rating of buy. At today's prices, RVMD is trading -47.22% away from its average analyst target price of $72.25 per share.

Over the last year, RVMD shares have gone down by -9.2%, which represents a difference of -30.3% when compared to the S&P 500. The stock's 52 week high is $62.4 per share and its 52 week low is $29.17.

None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.